Core Insights - The integration of technology and traditional Chinese medicine (TCM) is gaining momentum, with significant developments in AI applications within the industry [1][2] - Guoshengtang is positioning itself as a leader in TCM modernization and internationalization, aiming to enhance the quality and accessibility of TCM resources [1][3] Group 1: AI and Technology Integration - Guoshengtang has established strategic partnerships with top research teams to develop TCM-specific AI models, marking a shift from exploration to large-scale application [2][3] - The AI platform, "Guoyi AI Avatar," has achieved an expert simulation consistency of over 86%, enhancing the efficiency of online consultations and addressing the uneven distribution of quality medical resources [3][4] - The company has been building a digital infrastructure since 2019, accumulating extensive clinical data to support its AI initiatives [2][3] Group 2: Clinical Research and Evidence-Based Medicine - The launch of the "Xunyan Zhizhi" clinical research integration platform aims to address the challenges of evidence-based evaluation in TCM, utilizing AI to create a comprehensive innovation system [6][7] - This platform will facilitate the collection of accurate clinical data, enabling objective assessments of TCM efficacy and promoting a shift from experience-based to evidence-based medicine [6][7] Group 3: Global Expansion and Market Strategy - Guoshengtang is expanding its global footprint through a "merger + cooperation + self-built" strategy, with plans to acquire 14 clinics in Singapore and establish a joint venture with a digital healthcare platform [9][10] - The company has formed strategic partnerships with various platforms to enhance its service accessibility and user engagement, significantly increasing its customer acquisition rates [8][9] - By 2026, Guoshengtang plans to enter markets in Hong Kong and Malaysia, followed by expansion into Europe and the United States [1][9]

港澳台侨企业此番带来了中成药、保健品、生物科技、智慧医疗、人参滋补品等。展商普遍认为，吉林 在中医药原料(特别是长白山人参)生产方面具有突出优势，这是他们参展的主要原因。 中新网长春12月7日电 (记者 郭佳)2025长春国际医药健康产业博览会7日开幕。在港澳台侨展区，41家 企业集中展示了医药健康产品及AI诊疗设备。多位参展商表示，希望借展会契机，与吉林在人参和中 草药资源供应上建立更紧密合作。 长春市政协港澳台侨和外事委员会办公室主任车芳表示，港澳台侨展区既是展示窗口，也是连接原产地 与市场的平台。"希望通过展会促进港澳台侨企业与吉林在中医药、人参产业上的深入合作。"(完) 12月7日，吉林长春，观众在港澳台侨展区了解医药健康产品。 郭佳 摄 海外侨企则将合作重点放在供给端与国际市场的开拓上。多家机构认为，全球对中医药的需求不断上 升，但产品出海仍需依托稳定的原料供应链。 "吉林有好原料，我们有渠道。"世界华人企业家联合会全球总会理事长潘静雅说，侨界在多国布局了销 售网络，此次组团参展，希望推动吉林人参和中草药更系统地走向海外市场。 "我们未来主要的市场是内地。"山参有约健康科技(香港)有限公司首席科学顾 ...

Core Viewpoint - Yiling Pharmaceutical's innovative traditional Chinese medicine, Yangzheng Xiaojie Capsule, has been approved for sale in Thailand, marking a significant milestone in the company's internationalization strategy and highlighting the growing global recognition of traditional Chinese medicine in the oncology field [1][3]. Group 1: Product Approval and Significance - Yangzheng Xiaojie Capsule is the latest product from Yiling Pharmaceutical to receive registration in Thailand, following the success of Lianhua Qingwen Capsule, Shensong Yangxin Capsule, and Jinlidag Granules [1]. - The approval signifies the unique value of traditional Chinese medicine in cancer treatment is increasingly acknowledged internationally [1]. Group 2: Research and Efficacy - Joint research by Professor Jiang Wenguo from Cardiff University and Yiling Pharmaceutical found that Yangzheng Xiaojie Capsule significantly interferes with tumor cell invasion and metastasis by inhibiting the overactivation of the PI3K/Akt signaling pathway [2]. - Clinical studies led by Academician Yu Jinming showed that Yangzheng Xiaojie Capsule combined with chemotherapy significantly improved the quality of life for patients with advanced non-small cell lung cancer, with a clinical symptom improvement rate of 83.5% [2]. - Another study indicated that the combination of Yangzheng Xiaojie Capsule with interventional chemotherapy for primary liver cancer resulted in a total effective rate of 65.2%, significantly higher than the control group's 36.1% [2]. Group 3: Safety Profile - A meta-analysis involving 19 studies and 2,125 patients demonstrated that Yangzheng Xiaojie Capsule effectively alleviates gastrointestinal reactions caused by radiotherapy and chemotherapy, mitigates bone marrow suppression, and protects liver function, indicating good safety [3]. Group 4: Market Expansion - The approval of Yangzheng Xiaojie Capsule in Thailand is a vital step in Yiling Pharmaceutical's international strategy and serves as a practical example of traditional Chinese medicine contributing to the "Belt and Road" initiative [3]. - Yiling Pharmaceutical has successfully registered and launched 17 innovative traditional Chinese medicines in over 50 countries and regions worldwide [3].

Core Insights - Yangzheng Xiaojie Capsule is an innovative traditional Chinese medicine developed under the guidance of traditional Chinese medicine theory, targeting the pathological mechanisms of tumors and has been approved for use in primary liver cancer treatment in China [1][2] Group 1: Product Efficacy - Yangzheng Xiaojie Capsule integrates traditional methods with modern anti-cancer drugs, demonstrating a dual action of supporting the body while eliminating pathogens, which aligns with modern cancer treatment goals [1] - Clinical studies indicate that Yangzheng Xiaojie Capsule significantly improves the quality of life for patients with advanced non-small cell lung cancer, with a clinical symptom improvement rate of 83.5% [2] - In a study on primary liver cancer, the combination of Yangzheng Xiaojie Capsule with interventional chemotherapy resulted in a total effective rate of 65.2%, significantly higher than the control group's 36.1% [2] Group 2: Research and Validation - Research led by Professor Jiang Wenguo from Cardiff University found that Yangzheng Xiaojie Capsule can significantly interfere with tumor cell invasion and metastasis by inhibiting the excessive activation of the PI3K/AKT signaling pathway [1] - The same research also indicated that the capsule inhibits the activity of focal adhesion kinase, thereby suppressing tumor angiogenesis, which contributes to tumor starvation [1] Group 3: Market Expansion - Yangzheng Xiaojie Capsule has recently been approved in Thailand, marking a significant milestone in Yiling Pharmaceutical's internationalization strategy and demonstrating the practical application of traditional Chinese medicine in the "Belt and Road" initiative [4] - Yiling Pharmaceutical has successfully registered 17 innovative traditional Chinese medicines in over 50 countries and regions worldwide, indicating strong international market recognition [4]

11月25日-26日，"第八届'一带一路'中医药发展论坛暨第三届OTC品牌大会"在杭州举行。大会由中国非 处方药物协会、"一带一路"中医药发展论坛秘书处主办，浙江省医药行业协会、上海市食品药品安全研 究会联合主办。 本届大会汇聚了专家学者、国际代表、优秀企业家、媒体代表，为中医药发展与OTC品牌建设提供可落 地的品牌促进与国际化解决方案，通过深度交流共促健康行业高质量发展。 十二届全国政协副秘书长、教科文卫体委员会副主任张秋俭致辞表示，"一带一路"中医药的发展论坛已 成功举办八届，为推动中医药高质量融入"一带一路"建设，服务全球卫生健康事业，增进世界人民福祉 作出了重要贡献。她强调，"一带一路"上的中医药发展及OTC品牌发展，需进一步聚焦"做什么、怎么 做"的问题。中医药+OTC在"一带一路"平台实现世界共享，制定国际标准是关键，核心在于保障安全、 有效，最终实现中医药智慧与OTC品牌的高质量发展，为医药健康产业的发展进一步指明方向，打开更 多发展机遇的窗口。 中国非处方药物协会会长刘沛致辞指出，中医药及OTC行业肩负高质量发展使命，医药行业应坚持创新 驱动与国际化道路，让中国品牌"立起来、走出去"。国家标准 ...

Core Viewpoint - The "8th Belt and Road Traditional Chinese Medicine Development Forum and the 3rd OTC Brand Conference" aims to promote the high-quality development of the health industry through dialogue and collaboration among various stakeholders in the OTC and traditional Chinese medicine sectors [1][3]. Group 1: Conference Overview - The conference gathered representatives from "Belt and Road" countries, international organizations, regulatory bodies, industry experts, and media to create a dialogue platform for deep integration in the pharmaceutical and health sectors [3][7]. - The event focused on the innovative development of traditional Chinese medicine and the upgrading of OTC brands, providing actionable paths for brand cultivation and international practices [3]. Group 2: Key Speeches and Insights - The President of the China Non-Prescription Drug Association emphasized the importance of OTC as a vital part of the health service system, advocating for innovation-driven international development of Chinese brands [4]. - The Chairman of the Global Self-Care Federation highlighted China's significant role in strengthening global self-care systems and expressed a willingness to deepen cooperation with Chinese counterparts [4]. - Industry leaders discussed the transformation of consumer health markets and the importance of adapting traditional cultural symbols into globally recognized health values [5]. Group 3: Standards and Initiatives - The conference saw the release of the group standard for "Brand Value Evaluation of Non-Prescription Drug Enterprises," aimed at guiding the development of OTC brands and enhancing overall industry competitiveness [6]. - A new health education project titled "National 'Medicine' Health" was launched, designed to make professional medical knowledge accessible and engaging for the general public [6].

Core Viewpoint - The restructuring of the "National Key Laboratory of Traditional Chinese Medicine Quality" into the "National Key Laboratory of Traditional Chinese Medicine Mechanism and Quality" signifies a strategic shift towards understanding the scientific mechanisms behind traditional Chinese medicine (TCM), particularly its immune regulation capabilities [1][2][3]. Group 1: Research Focus and Direction - The laboratory's new focus on "mechanism" indicates a transition from traditional empirical validation to modern mechanistic explanations, aiming to clarify how TCM works scientifically [3]. - The primary research direction will be the immune regulation mechanisms of TCM, with an ambition to lead global research in this area within 3 to 5 years [2][3]. - The laboratory aims to establish scientific evidence for the mechanisms of TCM, which is essential for quality control and ensuring clinical efficacy and safety [3]. Group 2: Development and Innovation in Macau - Macau's TCM industry is still developing, with a focus on innovative TCM research rather than traditional manufacturing [4]. - The laboratory has multiple research centers that support the development of TCM in Macau, including a center focused on classic formulations expected to enter the market within one to two years [4]. - The establishment of a drug regulatory science research center at the University of Macau will provide quality inspection services for both TCM and Western medicine [4]. Group 3: Talent Recruitment and International Collaboration - The laboratory plans to recruit talent with a background in TCM from developed countries, emphasizing the importance of international scientific education and achievements [7][8]. - There is an openness to non-Chinese scientists joining the team, which is expected to enhance the modernization and internationalization of TCM [7][8]. - The laboratory aims to create an internationalized work environment to attract global talent while also nurturing local talent from Macau [8][9].

Core Viewpoint - The article emphasizes the importance of traditional Chinese medicine (TCM) internationalization through theoretical foundations, scientific innovation, and cultural integration, highlighting Yiling Pharmaceutical's efforts in promoting TCM globally [5][7][9]. Group 1: Theoretical Foundation and Academic Development - Yiling Pharmaceutical has established a comprehensive theoretical framework for "Luo Disease" over 33 years, which is considered a significant milestone in TCM development [5]. - The company has published several authoritative texts on Luo Disease, including "Luo Disease Studies" and "Meridian Theory," which are used in international educational institutions to train TCM professionals [5][6]. - Yiling has created multiple academic exchange platforms globally, including various international associations and conferences, to promote the study and dissemination of Luo Disease theory [6]. Group 2: Market Strategies and Cultural Integration - The company adopts a differentiated market strategy, "one country, one policy," to align with the medical needs and cultural contexts of different regions [7]. - In developed countries, Yiling focuses on high-level clinical research to gain trust from the academic and regulatory communities, while in emerging markets, it integrates products into local healthcare systems [7]. - The successful inclusion of Tongxinluo capsules in Vietnam's medical insurance directory exemplifies the company's effective local integration [7]. Group 3: Evidence-Based Research and International Recognition - Yiling Pharmaceutical has pioneered evidence-based research in TCM since 1995, establishing a robust research system and innovation platform [9][10]. - The company has conducted over 40 high-quality evidence-based studies on its 17 innovative TCM products, with significant findings published in prestigious international medical journals [9][10]. - These studies validate the efficacy and safety of TCM, presenting its wisdom in modern scientific language, thus facilitating international recognition [10]. Group 4: Future Outlook and Challenges - Yiling Pharmaceutical acknowledges the challenges of cultural recognition and regulatory policies in non-Belt and Road countries for TCM's international expansion [12]. - The company believes that collaboration among government, industry, academia, and research institutions is essential to overcome these barriers [12]. - There is confidence that by balancing tradition and innovation, TCM can contribute significantly to global health governance [12].

Core Insights - The "Belt and Road" Traditional Chinese Medicine Development Forum was held in Shanghai, focusing on the cultural dissemination and innovative development of traditional Chinese medicine (TCM) in the context of the Belt and Road Initiative [1] Group 1: Policy and Development - TCM is recognized as a living heritage that contributes significantly to global health systems, emphasizing the need for high-quality development driven by policy, technology, and talent [1] - There is a push for the digital standardization of TCM to align with international standards, facilitating its integration into global health frameworks [1] Group 2: International Collaboration - The forum highlighted the importance of leveraging time-honored brands and food-medicine integration products to promote TCM globally, advocating for localized production to enhance health awareness [1] - The establishment of 30 overseas centers and multilateral mechanisms aims to incorporate TCM into more national public health systems, creating accessible health products along the Belt and Road [1] Group 3: Industry Insights - Discussions at the forum included the international development and collaboration of TCM old brands and the innovative application of the food-medicine integration concept in the modern health industry [1] - Leaders from prominent TCM enterprises shared their experiences and strategies for expanding century-old brands into international markets [1]

固生堂 2024 年收入约 800 万新币，2025 年至今保持超 100%增长， 通过并购、合作、自建积极扩展海外市场，控股 OneDox 实现中西医结 合，收购大中堂增强市场控制力，新加坡首店月收入达 16-17 万新币， 回头率超 40%。 固生堂董事长持续增持公司股份，看好公司未来发展。国内市场方面， 2024 年以利润为主导，2025 年上半年利润增长显著。无锡地区在医保 政策严格管控下收入增长超 40%，区域利润率约 26%，显示出盈利能 力。 固生堂计划 2026 年进入香港和马来西亚市场，香港通过并购增加约 20 家诊所。公司人才策略是将中国优秀人才派驻海外担任总经理，构建本 地化运营团队，力争三年内成为当地中医领域头部企业。 新加坡中医支付主要依赖自费，但正推动中医药沙盒计划，未来可能纳 入医保体系。香港医疗券可用于中医诊所，商业保险也覆盖部分。公司 预计 2026 年海外收入规模将达数亿元人民币。 Q&A 固生堂 20251117 摘要 固生堂在新加坡的并购进展和战略布局是怎样的？ 固生堂于 2025 年 10 月与新加坡数字医疗平台 OneDox 达成战略合作，并在 2025 年 11 ...